Eupraxia Pharmaceuticals (EPRX)
Develops locally delivered, extended-release drug candidates using its Diffusphere microsphere technology.
$7.40
Pre-market−0.04 (−0.54%)
At close$7.44(+17.35%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions55 holders · as of Mar 31, 2026 | 66.39% | 22.23M ADS | |
| Otherremainder | 33.61% | 11.25M ADS |
33.48M ADS as of Aug 30, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Institutions13F, as of Mar 31, 2026
55 holders · 22.23M shares · 22 new positions · 41 increased · 6 reduced · 3 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Beutel, Goodman & Co Ltd. | 3.67M | 10.95% | −42.9K | May 15, 2026 |
| Affinity Asset Advisors, LLC | 1.59M | 4.75% | +1.29M | May 14, 2026 |
| Balyasny Asset Management L.P. | 1.35M | 4.03% | 0 | May 15, 2026 |
| Vivo Capital, LLC | 1.35M | 4.03% | 0 | May 20, 2026 |
| Scotia Capital Inc. | 1.34M | 4.01% | +56.0K | May 13, 2026 |
| Ikarian Capital, LLC | 1.21M | 3.63% | +604.7K | May 15, 2026 |
| Great Point Partners LLC | 1.20M | 3.58% | 0 | May 15, 2026 |
| Point72 Asset Management, L.P. | 967.6K | 2.89% | +255.5K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Joseph S. Freedman | 12.40% | 4.84M | Nov 7, 2024 ↗ | |
| Beutel, Goodman & Co Ltd. | 8.00% | 4.06M | 13G | Nov 14, 2025 ↗ |
| Manchester Management Company, LLC | 7.40% | 3.83M | 13G | May 12, 2026 ↗ |
| Robert Disbrow | 7.00% | 3.57M | 13G | Nov 14, 2025 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.